Loading…
PharmaCyte Biotech, Inc. is projected to rise to $0.7025 by 2027, a +22% move from its current price of $0.5758. PMCB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.5591 | $0.5755 | $0.5925 | -0.05% |
| Aug 6 | $0.5522 | $0.5753 | $0.5993 | -0.09% |
| Aug 7 | $0.5468 | $0.575 | $0.6046 | -0.14% |
| Aug 8 | $0.5423 | $0.5747 | $0.609 | -0.19% |
| Aug 9 | $0.5384 | $0.5744 | $0.6129 | -0.24% |
| Aug 10 | $0.5348 | $0.5742 | $0.6164 | -0.28% |
| Aug 11 | $0.5315 | $0.5739 | $0.6196 | -0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5315 | $0.5739 | $0.6196 | -0.33% |
| Week 2 | $0.5132 | $0.572 | $0.6375 | -0.66% |
| Week 3 | $0.4992 | $0.5701 | $0.6511 | -0.99% |
| Week 4 | $0.4874 | $0.5682 | $0.6624 | -1.31% |
| Week 5 | $0.4771 | $0.5664 | $0.6723 | -1.64% |
| Week 6 | $0.4678 | $0.5645 | $0.6811 | -1.96% |
| Week 7 | $0.4593 | $0.5626 | $0.6892 | -2.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PharmaCyte Biotech, Inc. is a biotechnology company focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States.
Its Cell-in-the-Box technology is a proprietary cellulose-based live cell encapsulation platform used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors.
The company has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment.
The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
PharmaCyte Biotech, Inc. (PMCB) is currently trading with a price of $0.6101 and a market capitalization of $6.55M. It is ranked 5176th by market cap among listed assets.
The near-term price picture is shaped by a bearish sentiment, with a current price near a defined support level and an upward resistance nearby. The overall price outlook shows a multi-year forecast that envisions a path of rising averages after 2026, culminating in meaningfully higher prices by mid-century.
Forecast highlights show a path from 2026 onward, with a 2026 average price of $0.6101 and a max of $0.7832, then climbing to higher averages such as $0.7901 in 2027 and $0.9076 in 2030, continuing to $1.58 in 2040 and $2.91 in 2050, with a max of $5.91 by 2050.
A major floor 23.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 34.8% above — a clean break opens room to run.
A major ceiling 65.1% above — clearing it would confirm fresh momentum.
Key PMCB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PMCB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5873 | Sell | $0.5897 | Sell |
| MA 10 | $0.5985 | Sell | $0.605 | Sell |
| MA 20 | $0.644 | Sell | $0.6372 | Sell |
| MA 50 | $0.7149 | Sell | $0.6887 | Sell |
| MA 100 | $0.7232 | Sell | $0.7256 | Sell |
| MA 200 | $0.781 | Sell | $0.809 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.77 | Neutral |
| Stoch RSI (14) | 8.99 | Buy |
| CCI (20) | -97.25 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -18.34 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.77 | Sell |
| Awesome (5,34) | -0.11 | Sell |
| Ultimate (7,14,28) | 28.15 | Buy |
| Momentum (10) | -0.06 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 0.58 | Sell |
| ADX (14) | 22.60 | Sell |
| ATR (14) | 0.02 | Info |
Near-term technical picture is BEARISH. The RSI(14) is 30, and the price momentum remains weak relative to recent levels.
The stock is trading below its SMA50 of $0.7459 and below its SMA200 of $0.7978, with support at $0.6101 and resistance at $0.828.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.5758 | $0.5758 | $0.7285 | 0% | Neutral | |
| $0.5573 | $0.7025 | $0.9381 | +22% | Bullish | |
| $0.5863 | $0.7617 | $1.06 | +32% | Bullish | |
| $0.5897 | $0.7855 | $1.13 | +36% | Bullish | |
| $0.5885 | $0.8014 | $1.18 | +39% | Bullish | |
| $0.5693 | $0.791 | $1.19 | +37% | Bullish | |
| $0.5724 | $0.8103 | $1.24 | +41% | Bullish | |
| $0.5784 | $0.8333 | $1.30 | +45% | Bullish | |
| $0.7006 | $1.03 | $1.63 | +78% | Bullish | |
| $0.7965 | $1.19 | $1.91 | +106% | Bullish | |
| $0.8381 | $1.34 | $2.31 | +133% | Bullish | |
| $1.38 | $2.50 | $4.73 | +335% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.5758 | $0.5758 | $0.6913 | +0.00% |
| September 2026 | $0.4667 | $0.5528 | $0.6737 | -3.99% |
| October 2026 | $0.4623 | $0.5515 | $0.6799 | -0.23% |
| November 2026 | $0.4807 | $0.577 | $0.7179 | +4.62% |
| December 2026 | $0.4812 | $0.5807 | $0.7285 | +0.64% |
Click any year to see its month-by-month PMCB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PMCB price prediction for 2026 points to an average of $0.5758 (low $0.5758, high $0.7285) — a potential gain of 0% on today's $0.5758. A consolidation phase looks the most probable path here.
In 2027, PMCB is projected to trade between $0.5573 and $0.9381, averaging $0.7025 — a potential gain of +22% from today's $0.5758. That is up +22% on the projected 2026 average. Momentum favours further upside here.
PharmaCyte Biotech, Inc.'s 2028 outlook centres on $0.7617, within a $0.5863 to $1.06 range. That is up +8% on the projected 2027 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, PMCB could reach as high as $1.13, with a base case around $0.7855 and support toward $0.5897 — roughly +36% from $0.5758. Momentum favours further upside here.
Expect PMCB to range from $0.5885 to $1.18 through 2030. The $0.8014 average target implies a +39% move from current prices. That is up +2% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The PMCB price prediction for 2031 points to an average of $0.791 (low $0.5693, high $1.19) — a potential gain of +37% on today's $0.5758. Momentum favours further upside here.
In 2032, PMCB is projected to trade between $0.5724 and $1.24, averaging $0.8103 — a potential gain of +41% from today's $0.5758. That is up +2% on the projected 2031 average. Buyers look set to stay in control over this stretch.
PharmaCyte Biotech, Inc.'s 2033 outlook centres on $0.8333, within a $0.5784 to $1.30 range. That is up +3% on the projected 2032 average. That marks a +45% change versus current levels. Momentum favours further upside here.
By 2034, PMCB could reach as high as $1.63, with a base case around $1.03 and support toward $0.7006 — roughly +78% from $0.5758. Buyers look set to stay in control over this stretch.
Expect PMCB to range from $0.7965 to $1.91 through 2035. The $1.19 average target implies a +106% move from current prices. That is up +16% on the projected 2034 average. Momentum favours further upside here.
The PMCB price prediction for 2040 points to an average of $1.34 (low $0.8381, high $2.31) — a potential gain of +133% on today's $0.5758. Buyers look set to stay in control over this stretch.
In 2050, PMCB is projected to trade between $1.38 and $4.73, averaging $2.50 — a potential gain of +335% from today's $0.5758. That is up +87% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PMCB today (≈ 1,736.714137 PMCB) could be worth
$4,346.6
+$3,346.6 (+335%) by 2050 · US Dollar
Based on the average projected PMCB price of $2.5 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PMCBwould be worth at today's price.
$1,000 invested in PMCB on Jul 31, 2025 (≈ 980.392175 PMCB) would be worth
$564.51
-$435.49 (-43.5%) today · 0.56× · US Dollar
Based on a PMCB entry price of $1.02 vs. today's $0.5758.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.6001 | $959.51 | -4.0% |
| 1 month ago | $0.741 | $777.06 | -22.3% |
| 3 months ago | $0.7553 | $762.35 | -23.8% |
| 6 months ago | $0.819 | $703.05 | -29.7% |
| 1 year ago | $1.02 | $564.51 | -43.5% |
| All time (5.0y) ago | $8.55 | $67.35 | -93.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PMCB forecast.
Our base-case forecast reaches $1.20 around 2040.
Implied market cap at $1.20: $12.88M
Looking out over multiple years, the forecast shows a bullish tilt beginning in 2027 and continuing through 2050. The 2026 forecast is min $0.6101, avg $0.6101, max $0.7832 with ROI of 0 and sentiment Neutral.
From 2027 onward, the averages rise to $0.7901 (2027), $0.8579 (2028), $0.8597 (2029), and $0.9076 (2030), with a 2030 max of $1.39 and a 2030 ROI of 48.8; sentiment is bullish. The path continues with higher years such as 2033 avg $0.9632 and 2034 avg $1.21, and culminating in 2040 avg $1.58 and 2050 avg $2.91, with 2040 max $2.90 and 2050 max $5.91; ROI values peak at 159.4% in 2040 and 376.8% by 2050. These are estimates, not guarantees, and involve uncertainty and risk.
Tap a question to reveal the answer.
The 2030 forecast shows min $0.6421, avg $0.9076, max $1.39 with ROI 48.8 and sentiment BULLISH.
The forecast turns neutral in 2026 with avg $0.6101, then bullish from 2027 onward, with 2027 avg $0.7901 and 2030 avg $0.9076; ROI grows to 29.5 (2027) and 48.8 (2030), rising further to 159.4 by 2040 and 376.8 by 2050, though these are estimates, not guarantees.
Yes. The 2030 forecast has a max of $1.39 and an average of $0.9076, with a low of $0.6421, implying a move above $1 within that year.
Current price is $0.6101 and market cap is $6.55M; the rank is 5176.
The near-term picture is BEARISH, with RSI(14) at 30. The price sits near support at $0.6101 and faces resistance at $0.828; the 30-day range runs from $0.4858 to $0.7663, and annualized volatility is 70.
PharmaCyte Biotech, Inc. Community Discussion
0Share your PharmaCyte Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.